Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 studies are ongoing to assess the ...

In the world of drug development, the leap from concept to clinic is often a long and winding road. But Creative Biolabs is quietly reshaping that journey—one assay, one chip, one insight at a time.

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolio Omeros is eligible to receive 340 million US dollars in ...

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk's Rare Disease portfolio Omeros is eligible to receive 340 million US dollars in ...

A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, scientists preserved cognition in mice without dulling the cancer-killing ...

That’s Hudson, Ohio for you – a town that somehow manages to be both frozen in time and completely alive. Just 30 miles southeast of Cleveland and 15 miles north of Akron, Hudson sits like a perfectly ...

Background Anti-C1q autoantibodies can disrupt normal complement function, contributing to the formation of pathogenic immune ...

Insilico announced the launch of its innovative cardiometabolic disease portfolio of unique highly-differentiated molecules ...

Insilico announced the launch of its innovative cardiometabolic disease portfolio at BIO Europe 2025. The portfolio covers a ...

A recent paper suggests a new form of inhibitory circuit in cortex, in which a pyramidal cell directly excites the presynaptic terminal of an inhibitory interneuron, allowing the rapid and powerful ...

Participants were presented with polyphonic music made of two monophonic streams (PolyOrig condition), with control stimuli where the average pi ...